BTCRC-LUN17-127 published in Lung Cancer Journal

A Big Ten Cancer Research Consortium study on plinabulin combined with nivolumab and ipilimumab for recurrent small cell lung cancer was published in Lung Cancer Journal. The study, BTCRC-LUN17-127, found the combination tolerable at 30 mg/m², though median progression-free survival was 1.6 months, below the target of 3.5 months. Some patients showed prolonged response.


Related News

BTCRC-LUN17-127 published in Lung Cancer Journal

A Big Ten Cancer Research Consortium study on plinabulin combined with nivolumab and ipilimumab for recurrent small cell lung cancer was published in Lung Cancer Journal. The study, BTCRC-LUN17-127, found the combination tolerable at 30 mg/m², though median progression-free survival was 1.6 months, below the target of 3.5 months. Some patients showed prolonged response.

© Copyright 2024. All Rights Reserved by MedPath